$TRLV

Trulieve Cannabis (TRLV) issued 10 million shares worth $55.5 million in an ESOP-related offering, causing a 6.5% stock price increase. The company also authorized a $50 million share buyback program. Analysts project varying revenue and earnings forecasts for 2029, with some seeing significant upside and others a more pessimistic outlook. Q2 2026 sales declined year over year, and net loss widened, keeping margin trends and capital deployment in focus.

Trulieve Cannabis Corp. (TRLV) completed its move from British Columbia to Delaware. The change, effective August 11, 2026, converted all outstanding shares and maintained the NYSE listing. Shareholder rights now follow Delaware law, with details in the proxy statement filed June 25, 2025.

MSOS, an ETF focused on cannabis stocks, reached its highest level in 2026. Trulieve, its largest holding, began trading on the NYSE under TRLV. The DEA hearing in June could reschedule marijuana, boosting the sector. MSOS has a 103.7% NAV return over one year, outperforming key indices. AdvisorShares and Alliance Global highlight potential benefits from rescheduling, including improved earnings and capital access.

Cannabis CEOs at Green Thumb (GTBIF), Curaleaf (CURLF) and Trulieve (TRLV) discussed potential demand and pricing effects from the Nov. 12 end of a federal loophole for hemp-derived THC products. Curaleaf estimates the hemp market at about $25B annually. Trulieve cites Florida hemp revenue of about $4B vs medical $2B. AdvisorShares MSOS is down 8% YTD.

Trulieve Cannabis Corp. (NYSE: TRLV) said it completed its redomicile from British Columbia to Delaware on Aug. 11, 2026, after shareholder approval on Aug. 5 and a British Columbia Supreme Court final order on Aug. 10. Trulieve’s subordinate voting shares continue trading on the NYSE as TRLV.

Trulieve Cannabis Corp. (TRLV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. In connection with the consummation of the Domestication and pursuant to the Company’s Certificate of Incorporation, Bylaws (as defined below) and the Delaware General Corporation Law (the “DGCL”), the Company has or will ent

FactSet says about 75% of S&P 500 companies reported Q2 results, with 85% beating analyst expectations. It estimates S&P 500 earnings up 50.4% year over year and revenue up about 15%, versus 12.2% expected. The article lists multiple stocks with EPS above consensus, including ESNT, FLR, TILE, and UAA.

Trulieve Cannabis reported Q2 revenue of $271 million, including $222 million medical-only revenue. Adjusted EBITDA was $98 million (36% margin). Operating cash flow was $53 million and free cash flow $32 million, with $325 million cash and $289 million debt. The company authorized a $50 million share repurchase program in June. It expects Q3 medical-only revenue comparable to $222 million and raised capex to $95 million.

The article says Virginia will start regulated adult-use cannabis sales on July 1, 2027, with up to 350 retail dispensaries, and highlights Green Thumb Industries’ existing Virginia medical footprint. It cites Green Thumb Q2 2026 results: $306.7M revenue, $84.3M normalized EBITDA, $29M operating cash flow, $283.6M cash. It also notes Texas awarded conditional licenses to Trulieve and Green Thumb.

Simply Wall St says Trulieve Cannabis (NYSE: TRLV) reported Q2 2026 sales of $271.0M, down from $302.1M, while net loss widened to $406.0M. Loss per share from continuing operations rose to $2.10 from $0.07. For 1H 2026, sales fell to $557.7M and net loss to $403.6M. The piece discusses how federal rescheduling, costs, and a $50M buyback authorization could affect the investment outlook.